Envista Holdings Corporation reports recurring developments as a global dental products company serving dental professionals through consumables, technologies, equipment and services. Its public updates center on quarterly results, core sales trends, adjusted earnings measures, cash flow, share repurchase activity and management presentations at healthcare conferences.
Company news also covers product and brand activity across DEXIS, Kerr, Nobel Biocare and Ormco, including dental implants, orthodontics, digital imaging, restorative and endodontic solutions. Recent product announcements include Kerr Dental's ZenSeal Pro with ZenSave Tips, reflecting Envista's focus on dental workflow, treatment technology and clinician-facing product commercialization.
Envista Holdings Corporation (NYSE: NVST) has announced the registration for its third annual Envista Summit, to be held in Anaheim, California, from February 15-17, 2024. The event aims to unite the dental community, showcasing innovations and workflow improvements through presentations and hands-on workshops. The successful 2023 Summit in Las Vegas attracted nearly 1,500 professionals, featuring over 100 experts and extensive training sessions. Envista's CEO, Amir Aghdaei, emphasizes the goal of empowering dental practices through advanced tools and knowledge. Registrants can earn continuing education credits while enhancing patient care and operational efficiency.
Summary not available.
Envista Holdings Corporation (NYSE: NVST) reported a 1.4% increase in sales to $660.8 million for Q4 2022, with core sales growth of 2.3% year-over-year. Net income reached $73.5 million, or $0.42 per diluted share, while adjusted net income rose to $91.9 million ($0.52 per diluted share), up from $81.1 million ($0.46) in Q4 2021. Adjusted EBITDA was $138.3 million, compared to $120.7 million the previous year. For 2023, Envista anticipates low-single digit core sales growth and an adjusted EBITDA margin exceeding 20%.
On January 30, 2023, Envista Holdings Corporation (NYSE: NVST) announced an Investor Access Event scheduled for February 24, 2023, from 8:00 am to 10:00 am PT at the Envista Summit. This hybrid event will feature a management presentation followed by a Q&A session. The Envista Summit aims to provide dental professionals with premium training across specialties like implantology, orthodontics, and endodontics, alongside digital dentistry training. For further details, visit the Envista Summit website.
Envista Holdings Corporation (NYSE: NVST) is set to report its fourth quarter 2022 financial results on February 8, 2023. A conference call to discuss these results will begin at 2:00 PM PT, lasting approximately one hour. The call will be accessible via the company's website, and a replay will be available shortly after. Envista, recognized for its extensive range of dental brands like Nobel Biocare and Ormco, focuses on enhancing patient care with innovative dental solutions and technologies, making it a significant player in the global dental products market.
Envista Holdings Corporation (NYSE: NVST) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, from 3:00 – 3:40 PM PT at the Westin St. Francis Hotel in San Francisco. Investors can access a live audio webcast and recording on Envista's Investor Relations website for 30 days post-event. Envista is a leading global dental products company with a portfolio of over 30 trusted dental brands, including Nobel Biocare and Ormco, focused on improving lives through innovative dental solutions and technology.
On November 7, 2022, Envista Holdings Corporation (NYSE: NVST) announced its upcoming participation in the Evercore ISI 5th Annual HEALTHCONx Conference. The virtual event will take place on November 30, 2022, from 11:20 AM to 12:05 PM ET. Investors can access live streams and recordings via Envista's Investor Relations website under Events and Presentations. Envista, a leading global dental products company, offers a diverse portfolio including dental implants, orthodontics, and digital imaging technologies, aimed at enhancing patient care.
Envista Holdings Corporation (NYSE: NVST) reported a 3.9% increase in sales for Q3 2022, totaling $631.1 million. Core sales growth stood at 4.9% compared to Q3 2021. Net income reached $49.6 million, translating to $0.28 per diluted share, while adjusted net income improved to $82.5 million or $0.47 per diluted share. Adjusted EBITDA rose to $127.6 million, reflecting a 20.2% margin. Despite economic challenges, the company maintains its guidance for mid-single-digit core sales growth and a 20% adjusted EBITDA margin for 2022.
Envista Holdings Corporation (NYSE: NVST) announced its participation in the Jefferies London Healthcare Conference on November 17, 2022, from 9:45 - 10:15 AM GMT. Investors can access audio recordings of the event via the Investor Relations section on Envista's website. Envista, a leading global dental products company with over 30 renowned brands, focuses on enhancing patient care through innovative solutions and services.
Summary not available.